Yang Yuhan, Sun Ziyi, Sun Xiaoning, Zhang Jin, Tong Tong, Zhang Xiaoxiao, Yao Kuiwu
Guang' anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Academic Management Service, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol. 2024 Sep 11;15:1452545. doi: 10.3389/fphar.2024.1452545. eCollection 2024.
Salvianolic acid B is the most abundant water-soluble component in the traditional Chinese medicine Danshen and can reduce myocardial ischemia-reperfusion (MI/R) injury through multiple targets and pathways. However, the role of SalB in protecting the myocardium from ischemia/reperfusion injury remains unclear.
To perform a preclinical systematic review and meta-analysis to assess the efficacy of Sal B in an animal model of myocardial infarction/reperfusion (MI/R) and to summarize the potential mechanisms of Sal B against MI/R.
Studies published from inception to March 2024 were systematically searched in PubMed, Web of Science, Embase, China National Knowledge Infrastructure Wanfang, and VIP databases. The methodological quality was determined using the SYRCLE RoB tool. The R software was used to analyze the data. The potential mechanisms are categorized and summarized.
32 studies containing 732 animals were included. The results of the meta-analysis showed that Sal B reduced myocardial infarct size ( < 0.01), and the cardiological indices of CK-MB ( < 0.01), CK ( < 0.01), LDH ( < 0.01), and cTnI ( < 0.01) compared to the control group. In addition, Sal B increased cardiac function indices, such as LVFS ( < 0.01), -dp/dt max ( < 0.01), +dp/dt max ( < 0.01), and cardiac output ( < 0.01). The protective effects of Sal B on the myocardium after I/R may be mediated by attenuating oxidative stress and inflammation, promoting neovascularization, regulating vascular function, and attenuating cardiac myocyte apoptosis. Publication bias was observed in all the included studies. Further studies are required to elucidate the extent of the cardioprotective effects of SalB and the safety of its use.
To the best of our knowledge, this is the first meta-analysis of Sal B in the treatment of MI/R injury, and Sal B demonstrated a positive effect on MI/R injury through the modulation of key pathological indicators and multiple signaling pathways. Further studies are needed to elucidate the extent to which SalB exerts its cardioprotective effects and the safety of its use.
丹酚酸B是中药丹参中含量最丰富的水溶性成分，可通过多个靶点和途径减轻心肌缺血再灌注（MI/R）损伤。然而，丹酚酸B在保护心肌免受缺血/再灌注损伤中的作用仍不清楚。
进行一项临床前系统评价和荟萃分析，以评估丹酚酸B在心肌梗死/再灌注（MI/R）动物模型中的疗效，并总结丹酚酸B对抗MI/R的潜在机制。
在PubMed、Web of Science、Embase、中国知网、万方和维普数据库中系统检索从创刊到2024年3月发表的研究。使用SYRCLE RoB工具确定方法学质量。使用R软件分析数据。对潜在机制进行分类和总结。
纳入32项研究，共732只动物。荟萃分析结果显示，与对照组相比，丹酚酸B减小了心肌梗死面积（<0.01），降低了心肌酶谱指标肌酸激酶同工酶（CK-MB，<0.01）、肌酸激酶（CK，<0.01）、乳酸脱氢酶（LDH，<0.01）和心肌肌钙蛋白I（cTnI，<0.01）。此外，丹酚酸B提高了心功能指标，如左心室短轴缩短率（LVFS，<0.01）、左室内压最大下降速率（-dp/dt max，<0.01）、左室内压最大上升速率（+dp/dt max，<0.01）和心输出量（<0.01）。丹酚酸B对I/R后心肌的保护作用可能是通过减轻氧化应激和炎症、促进新生血管形成、调节血管功能以及减轻心肌细胞凋亡来介导的。在所有纳入研究中均观察到发表偏倚。需要进一步研究以阐明丹酚酸B心脏保护作用的程度及其使用安全性。
据我们所知，这是首次对丹酚酸B治疗MI/R损伤进行的荟萃分析，丹酚酸B通过调节关键病理指标和多个信号通路对MI/R损伤显示出积极作用。需要进一步研究以阐明丹酚酸B发挥其心脏保护作用的程度及其使用安全性。
